Market Research Logo

Global Neuroblastoma Drugs Market 2019-2023

Global Neuroblastoma Drugs Market 2019-2023

About this market

Neuroblastoma is the most common type of childhood cancer. and its incidence is gradually increasing across the world. The exact etiological factor contributing to neuroblastoma remains undefined. However, the rising birth rate is a major contributor to the growing incidence of neuroblastoma. The incidence of neuroblastoma is increasing in developed as well as developing countries. Thus, the rising incidence of neuroblastoma is one of the driving factors for the market growth. Technavio’s analysts have predicted that the neuroblastoma drugs market will register a CAGR of over 4% by 2023.

Market Overview

Growing demand for anti-GD2 antibodies

The identification of the therapeutic targets on tumor cells or within the signaling cascade that leads to tumor growth is a promising field in cancer research. GD2 (O-acetyl-GD2 ganglioside) has been identified as a cell surface antigen that is overexpressed in neuroblastoma. These drugs do not pose any cytotoxic effects in the body. Therefore, physicians are switching toward prescribing anti-GD2 monoclonal antibodies for the treatment of neuroblastoma.

High cost of treatment

Children with neuroblastoma typically undergo many rounds of complex and intensive treatment, comprising several cycles of chemotherapy. The long duration increases the treatment costs. Drugs for the treatment of neuroblastoma, especially immunotherapy drugs, are considerably expensive. This increases the manufacturing costs of these drugs and subsequently the prices.

For the detailed list of factors that will drive and challenge the growth of the neuroblastoma drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


PRESS RELEASE

Technavio Announces the Publication of its Research Report – Global Neuroblastoma Drugs Market 2019-2023

Technavio recognizes the following companies as the key players in the global neuroblastoma drugs market: Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Teva Pharmaceutical, United Therapeutics.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the improvements in research and development for treatment of relapsed refractory neuroblastoma.”

According to the report, one of the major drivers for this market is the orphan drug incentives for neuroblastoma.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of available drugs.

Companies Mentioned

Bristol-Myers Squibb

Johnson & Johnson

Pfizer

Teva Pharmaceutical

and United Therapeutics

  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global oncology therapeutics market
      • Table Segments of global oncology therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Pipeline analysis
    • Table Pipeline molecules for neuroblastoma
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Chemotherapy - Market size and forecast 2018-2023
      • Table Chemotherapy - Market size and forecast 2018-2023 ($ millions)
      • Table Chemotherapy - Year-over-year growth 2019-2023 (%)
    • Immunotherapy - Market size and forecast 2018-2023
      • Table Immunotherapy - Market size and forecast 2018-2023 ($ millions)
      • Table Immunotherapy - Year-over-year growth 2019-2023 (%)
    • Others - Market size and forecast 2018-2023
      • Table Others - Market size and forecast 2018-2023 ($ millions)
      • Table Others - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Quarterly sales for UNITUXIN in $ millions
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Improvements in research and development for treatment of relapsed refractory neuroblastoma
      • Table Novel therapies under research and development for neuroblastoma
    • Availability of improved diagnostic modalities
    • Rising number of patient support initiatives
      • Table Patient support initiatives for neuroblastoma
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb - Vendor overview
      • Table Bristol-Myers Squibb - Business segments
      • Table Bristol-Myers Squibb - Organizational developments
      • Table Bristol-Myers Squibb - Geographic focus
      • Table Bristol-Myers Squibb - Key offerings
    • Johnson & Johnson
      • Table Johnson & Johnson - Vendor overview
      • Table Johnson & Johnson - Business segments
      • Table Johnson & Johnson - Organizational developments
      • Table Johnson & Johnson - Geographic focus
      • Table Johnson & Johnson - Segment focus
      • Table Johnson & Johnson - Key offerings
    • Pfizer
      • Table Pfizer - Vendor overview
      • Table Pfizer - Business segments
      • Table Pfizer - Organizational developments
      • Table Pfizer - Geographic focus
      • Table Pfizer - Segment focus
      • Table Pfizer - Key offerings
    • Teva Pharmaceutical
      • Table Teva Pharmaceutical - Vendor overview
      • Table Teva Pharmaceutical - Business segments
      • Table Teva Pharmaceutical - Organizational developments
      • Table Teva Pharmaceutical - Geographic focus
      • Table Teva Pharmaceutical - Segment focus
      • Table Teva Pharmaceutical - Key offerings
    • United Therapeutics
      • Table United Therapeutics - Vendor overview
      • Table United Therapeutics - Business segments
      • Table United Therapeutics - Organizational developments
      • Table United Therapeutics - Geographic focus
      • Table United Therapeutics - Key offerings
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report